Lupin arm gets Health Canada nod to market generic version of Spiriva for COPD

Mumbai: Global pharma major Lupin Limited has announced that its Canada subsidiary, Lupin Pharma Canada Ltd., has received approval from Health Canada to market a generic version of Spiriva (tiotropium bromide inhalation powder) for the treatment of chronic obstructive pulmonary disease (COPD), in Canada.

Tiotropium Bromide Inhalation Powder is indicated for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema. It is also used to relieve wheezing, shortness of breath, coughing, and chest tightness in patients with COPD.

Read also: Lupin Gets CDSCO Panel Nod for Phase IV CT of pulmonary FDC drug

"This approval of the first generic for Tiotropium Bromide Inhalation Powder by Health Canada underscores our commitment to bring affordable options of complex products for patients in Canada, particularly in the respiratory therapeutic area,” said, Dr. Sofia Mumtaz, President – Legal, Canada, Australia, and Japan.

Tiotropium Bromide Inhalation Powder (RLD Spiriva) had estimated annual sales of USD 42 million in Canada (IQVIA MAT Q4 of 2022).

Read also: Lupin Diagnostics unveils Satellite Laboratory in Vijayawada

Read also: Lupin Diagnostics unveils Regional Reference Laboratory in Bengaluru